A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan war veterans

American Journal of Psychiatry

Volumn 171, Issue 6, 2014, Pages 640-648

  Rothbaum, Barbara Olasov ^a   Price, Matthew ^a   Jovanovic, Tanja ^a   Norrholm, Seth D ^a   Gerardi, Maryrose ^a   Dunlop, Boadie ^a   Davis, Michael ^a   Bradley, Bekh ^a   Duncan, Erica J ^a   Rizzo, Albert ^a   Ressler, Kerry J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; CYCLOSERINE; HYDROCORTISONE; PLACEBO;

ADULT; AFGHANISTAN; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HORMONE RESPONSE; HUMAN; IRAQ; LEARNING; MAJOR CLINICAL STUDY; MALE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REINFORCEMENT; STARTLE REFLEX; TREATMENT DURATION; TREATMENT RESPONSE; VETERAN; VIRTUAL REALITY EXPOSURE THERAPY;

ADULT; AFGHAN CAMPAIGN 2001-; ALPRAZOLAM; ANTI-ANXIETY AGENTS; COMBINED MODALITY THERAPY; CYCLOSERINE; DOUBLE-BLIND METHOD; EXTINCTION, PSYCHOLOGICAL; FEMALE; HUMANS; IRAQ WAR, 2003-2011; MALE; PSYCHIATRIC STATUS RATING SCALES; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME; VETERANS; VIRTUAL REALITY EXPOSURE THERAPY;

EID: 84901847975     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2014.13121625     Document Type: Article

References (35)

1. Committee on the Assessment of Ongoing Effects in the Treatment of Posttraumatic Stress Disorder, Institute of Medicine: Summary, in Treatment for Posttraumatic Stress Disorder in Military and Veteran Populations: Initial Assessment. Washington, DC, National Academies Press, 2012, pp 1-16
2. Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL: Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med 2004; 351:13-22 (Pubitemid 38857243)
3. Institute of Medicine: Treatment of Posttraumatic Stress Disorder: An Assessment of the Evidence. Washington, DC, National Academies Press, 2008
4. Foa EB, Hembree E, Rothbaum BO: Prolonged Exposure Therapy for PTSD: Emotional Processing of Traumatic Experiences, Therapist Guide. New York, Oxford University Press, 2007
5. Gerardi M, Cukor J, Difede J, Rizzo A, Rothbaum BO: Virtual reality exposure therapy for post-traumatic stress disorder and other anxiety disorders. Curr Psychiatry Rep 2010; 12:298-305
6. Gerardi M, Rothbaum BO, Ressler K, Heekin M, Rizzo A: Virtual reality exposure therapy using a virtual Iraq: case report. J Trauma Stress 2008; 21:209-213 (Pubitemid 351655758)
7. Foa EB, Rothbaum BO: Treating the Trauma of Rape: Cognitive-Behavior Therapy for PTSD. New York, Guilford Press, 1998
8. Walker DL, Ressler KJ, Lu KT, Davis M: Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci 2002; 22:2343-2351 (Pubitemid 35386533)
9. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, Hodges L, Davis M: Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004; 61:1136-1144 (Pubitemid 39463415)
10. Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, Dadds MR: A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 2008; 63:544-549
11. Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, Hofmann SG, Eisenmenger K, Krystal JH, Pollack MH: Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry 2010; 67:365-370
12. Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, McCabe J, Peterson J, Foa EB: D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry 2007; 62:835-838 (Pubitemid 47488217)
13. Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, Cannistraro P, Jenike MA, Rauch SL: Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry 2008; 165:335-341 (Pubitemid 351704489)
14. Hofmann SG, Smits JA, Rosenfield D, Simon N, Otto MW, Meuret AE, Marques L, Fang A, Tart C, Pollack MH: D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry 2013; 170:751-758
15. Bouton ME, Kenney FA, Rosengard C: State-dependent fear extinction with two benzodiazepine tranquilizers. Behav Neurosci 1990; 104:44-55 (Pubitemid 20138261)
16. Lund BC, Bernardy NC, Vaughan-Sarrazin M, Alexander B, Friedman MJ: Patient and facility characteristics associated with benzodiazepine prescribing for veterans with PTSD. Psychiatr Serv 2013; 64:149-155
17. Management of Post-Traumatic Stress Working Group: VA/DoD Clinical Practice Guideline for Management of Post-Traumatic Stress. Washington, DC, Department of Veterans Affairs, Department of Defense, 2010
18. de Kleine RA, Hendriks GJ, Kusters WJ, Broekman TG, van Minnen A: A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol Psychiatry 2012; 71:962-968
19. Litz BT, Salters-Pedneault K, Steenkamp MM, Hermos JA, Bryant RA, Otto MW, Hofmann SG: A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res 2012; 46:1184-1190
20. Difede J, Cukor J, Wyka K, Olden M, Hunter H, Lee FS, Altemus M: D-cycloserine augmentation of exposure therapy for posttraumatic stress disorder: a pilot randomized clinical trial. Neuropsychopharmacol (Epub ahead of print, Nov 12, 2013)
21. Vermetten E, Vythilingam M, Schmahl C, De Kloet C, Southwick SM, Charney DS, Bremner JD: Alterations in stress reactivity after long-term treatment with paroxetine in women with posttraumatic stress disorder. Ann N Y Acad Sci 2006; 1071:184-202 (Pubitemid 44126728)
22. Orr SP, Roth WT: Psychophysiological assessment: clinical applications for PTSD. J Affect Disord 2000; 61:225-240 (Pubitemid 32119269)
23. Norrholm SD, Jovanovic T, Olin IW, Sands LA, Karapanou I, Bradley B, Ressler KJ: Fear extinction in traumatized civilians with posttraumatic stress disorder: relation to symptom severity. Biol Psychiatry 2011; 69:556-563
24. Smits JA, Rosenfield D, Otto MW, Powers MB, Hofmann SG, Telch MJ, Pollack MH, Tart CD: D-Cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry 2013; 73:1054-1058
25. Smits JA, Rosenfield D, Otto MW, Marques L, Davis ML, Meuret AE, Simon NM, Pollack MH, Hofmann SG: D-Cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J Psychiatr Res 2013; 47:1455-1461
26. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM: The development of a Clinician-Administered PTSD Scale. J Trauma Stress 1995; 8:75-90
27. Sheehan DV, Lecrubier Y, Sheehan KH: The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSMIV and ICD-10. J Clin Psychiatry 1998; 1959:22-33
28. Foa EB, Riggs DS, Dancu CV, Rothbaum BO: Reliability and validity of a brief instrument for assessing post-traumatic stress disorder. J Trauma Stress 1993; 6:459-473 (Pubitemid 24208473)
29. Preacher KJ, Curran PJ, Bauer DJ: Computational tools for probing interactions in multiple linear regression: multilevel modeling, and latent curve analysis. J Educ Behav Stat 2006; 31:437-448 (Pubitemid 44917080)
30. Reger GM, Gahm GA: Virtual reality exposure therapy for active duty soldiers. J Clin Psychol 2008; 64:940-946
31. Eftekhari A, Ruzek JI, Crowley JJ, Rosen CS, Greenbaum MA, Karlin BE: Effectiveness of national implementation of prolonged exposure therapy in Veterans Affairs care. JAMA Psychiatry 2013; 70:949-955
32. Ledgerwood L, Richardson R, Cranney J: D-Cycloserine and the facilitation of extinction of conditioned fear: consequences for reinstatement. Behav Neurosci 2004; 118:505-513 (Pubitemid 38685318)
33. Guastella AJ, Lovibond PF, Dadds MR, Mitchell P, Richardson R: A randomized controlled trial of the effect of D-cycloserine on extinction and fear conditioning in humans. Behav Res Ther 2007; 45:663-672 (Pubitemid 46282625)
34. Kuriyama K, Honma M, Yoshiike T, Kim Y: Valproic acid but not D-cycloserine facilitates sleep-dependent offline learning of extinction and habituation of conditioned fear in humans. Neuropharmacology 2013; 64:424-431
35. Chasson GS, Buhlmann U, Tolin DF, Rao SR, Reese HE, Rowley T, Welsh KS, Wilhelm S: Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine. Behav Res Ther 2010; 48:675-679